Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials

Zippi, 2014, Extraintestinal manifestations in a large series of Italian inflammatory bowel disease patients, World J Gastroenterol, 20, 17463, 10.3748/wjg.v20.i46.17463

Ott, 2013, Extraintestinal manifestations and complications in IBD, Nat Rev Gastroenterol Hepatol, 10, 585, 10.1038/nrgastro.2013.117

Veloso, 2011, Extraintestinal manifestations of inflammatory bowel disease: do they influence treatment and outcome, World J Gastroenterol, 17, 2702, 10.3748/wjg.v17.i22.2702

Vavricka, 2015, Extraintestinal manifestations of inflammatory bowel disease, Inflamm Bowel Dis, 21, 1982, 10.1097/MIB.0000000000000392

Arvikar, 2011, Inflammatory bowel disease associated arthropathy, Curr Rev Musculoskelet Med, 4, 123, 10.1007/s12178-011-9085-8

Harbord, 2016, The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease, J Crohns Colitis, 10, 239, 10.1093/ecco-jcc/jjv213

Vavricka, 2017, Anti-TNF treatment for extraintestinal manifestations of inflammatory bowel disease in the Swiss IBD Cohort Study, Inflamm Bowel Dis, 23, 1174, 10.1097/MIB.0000000000001109

Peyrin-Biroulet, 2017, Systematic review of tumor necrosis factor antagonists in extraintestinal manifestations in inflammatory bowel disease, Clin Gastroenterol Hepatol, 15, 25, 10.1016/j.cgh.2016.06.025

Roda, 2016, Loss of response to anti-TNFs: definition, epidemiology, and management, Clin Transl Gastroenterol, 7, e135, 10.1038/ctg.2015.63

Nyboe Andersen, 2015, Association between tumour necrosis factor-α inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study, BMJ, 350, h2809, 10.1136/bmj.h2809

Thiebault, 2016, Paradoxical articular manifestations in patients with inflammatory bowel diseases treated with infliximab, Eur J Gastroenterol Hepatol, 28, 876, 10.1097/MEG.0000000000000643

Rahier, 2010, Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy, Clin Gastroenterol Hepatol, 8, 1048, 10.1016/j.cgh.2010.07.022

2014, Entyvio® [package insert]

2014, Entyvio® [Summary of Product Characteristics]

Wyant, 2016, An overview of the mechanism of action of the monoclonal antibody vedolizumab, J Crohns Colitis, 10, 1437, 10.1093/ecco-jcc/jjw092

Feagan, 2013, Vedolizumab as induction and maintenance therapy for ulcerative colitis, N Engl J Med, 369, 699, 10.1056/NEJMoa1215734

Sandborn, 2013, Vedolizumab as induction and maintenance therapy for Crohn’s disease, N Engl J Med, 369, 711, 10.1056/NEJMoa1215739

Sands, 2014, Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed, Gastroenterology, 147, 618, 10.1053/j.gastro.2014.05.008

Loftus, 2017, Long-term efficacy of vedolizumab for ulcerative colitis, J Crohns Colitis, 11, 400

Vermeire, 2017, Long-term efficacy of vedolizumab for Crohn’s disease, J Crohns Colitis, 11, 412

Colombel, 2017, The safety of vedolizumab for ulcerative colitis and Crohn’s disease, Gut, 66, 839, 10.1136/gutjnl-2015-311079

Ungaro, 2017, A description of joint-related events in patients receiving vedolizumab from clinical and post-marketing safety experience, Inflamm Bowel Dis, 23, S47

Dulai, 2016, The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn’s disease: results from the US VICTORY Consortium, Am J Gastroenterol, 111, 1147, 10.1038/ajg.2016.236

Tadbiri, 2018, Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort, Aliment Pharmacol Ther, 47, 485, 10.1111/apt.14419

Hanauer, 2002, Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial, Lancet, 359, 1541, 10.1016/S0140-6736(02)08512-4

Feagan, 2016, Ustekinumab as induction and maintenance therapy for Crohn’s disease, N Engl J Med, 375, 1946, 10.1056/NEJMoa1602773

Juillerat, 2007, Extraintestinal manifestations of Crohn’s disease, Digestion, 76, 141, 10.1159/000111029

Mattheakis, 2016, PTG-100, an oral peptide antagonist of integrin α4β7 that alters trafficking of gut homing T cells in preclinical animal models, Inflamm Bowel Dis, 22, S48, 10.1097/01.MIB.0000480232.55276.b3